Tozorakimab

6 trials 2 recruiting

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

4 Completed trials

1 Sponsors

19 Countries

Phase III

Phase II

Phase III: 5 Phase II: 1

Oversight events:

2 serious breaches across 2 trials

View oversight register →

Indications tested

Chronic obstructive pulmonary disease 4 Acute respiratory failure 1 Asthma 1

Sponsors using this IMP

AstraZeneca AB 6

All trials

6 total

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting

2023-507031-38-00 Phase III 14 countries Astrazeneca AB
Dose Range Finding Study to Access Efficacy and Safety of Tozorakimab in Adults with Uncontrolled Asthma on Medium-to-High Dose Inhaled Cort… Recruiting

2024-519116-14-00 Phase II 5 countries AstraZeneca AB
"Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended

2023-505543-39-00 Phase III 12 countries Astrazeneca AB
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Phase III 17 countries Astrazeneca AB
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Phase III 6 countries AstraZeneca AB
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503571-19-00 Phase III 11 countries AstraZeneca AB

Showing 1–6 of 6 trials

← All drugs A–Z